XOMA

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif., Dec.  02, 2019  (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights Offering”). Under the terms of the Rights Offering, the holders of XOMA’s common stock and Series X Preferred Stock and Series Y Preferred Stock as of 5:00 p.m., New York time, on November 29, 2019, the record date for the Rights Offering, are entitled to purchase up to 1,000,000 shares of common stock in the aggregate at a subscription price equal to $22.00 per share, or under certain circumstances, shares of non-voting Series Z preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated December 2, 2019, relating to the Rights Offering.

XOMA Announces Commencement of Rights Offering

EMERYVILLE, Calif., Nov.  19, 2019  (GLOBE NEWSWIRE) --  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its intent to commence a rights offering pursuant to which the Company would raise approximately $22 million through the distribution of subscription rights to holders of its common stock (“Common Stock”), Series X preferred stock (“Series X Preferred”) and Series Y preferred stock (“Series Y Preferred”), which will entitle the holders to purchase shares of XOMA’s Common Stock at $22.00 per share (the “Rights Offering”). The Rights Offering will be fully backstopped by BVF Partners L.P., the Company's largest stockholder, or its assignee/transferee, which has agreed to purchase at a minimum its as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the Rights Offering for a total of up to $22 million.

XOMA Announces Proposed Rights Offering

Includes royalty interest in NIR178 Includes royalty interest in NIR178

XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

EMERYVILLE, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global Healthcare Conference, taking place October 2-4, 2019, in New York, New York.  The presentation will take place on Wednesday, October 2, 2019 at 7:45AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at  www.xoma.com .  An archived version of the webcast will be available for 90 days after the event.

XOMA to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

EMERYVILLE, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21st Annual Global Investment Conference, in New York, New York.  The presentation will take place on Tuesday, September 10, 2019, at 10:00AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at  www.xoma.com  or by clicking  http://wsw.com/webcast/hcw5/xoma/ .  An archived version of the webcast will be available for 90 days after the event.

XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for

Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates

Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know

Core Laboratories Inc

Ensco

Hess

Oceaneering

Exxon Mobil

After years of decline, spending on offshore oil projects is on track to bounce back in 2019.

The Offshore Drilling Rebound Has Finally Arrived

News for XOMA Stock (XOMA)